Rosen Law Firm Announces Investigation of Palomar Medical Technologies, Inc. in Connection with Its Sale to Cynosure, Inc. - PMTI
NEW YORK--(BUSINESS WIRE)-- The Rosen Law Firm, P.A. is investigating the Board of Directors of Palomar Medical Technologies, Inc. ("Palomar" or the "Company") (NASDAQ GS: PMTI) for possible breaches of fiduciary duty and other violations of state law in connection with its sale of the Company to Cynosure, Inc. (NASDAQ GS: CYNO).
If you would like to join the action please email or call Phillip Kim or Kevin Chan, toll-free, at 866-767-3653; or email at firstname.lastname@example.org or email@example.com. There is no cost or obligation to you.
Under the terms of the transaction, shareholders will receive $13.65 for each share of Palomar stock they own - $6.825 per share in cash and $6.825 per share in Cynosure common stock. The investigation relates to whether the price of $13.65 per share in cash and Cynosure stock is fair to public shareholders and whether PMTI's Board breached its fiduciary duties in connection with the transaction.
If you own Palomar common stock and wish to obtain additional information, you may contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
The Rosen Law Firm P.A.
Phillip Kim, Esq.
Laurence Rosen, Esq.
275 Madison Avenue 34th Floor
New York, New York 10016
Weekends Tel: 917-562-8616
Toll Free: 1-866-767-3653
KEYWORDS: United States North America New York
The article Rosen Law Firm Announces Investigation of Palomar Medical Technologies, Inc. in Connection with Its Sale to Cynosure, Inc. - PMTI originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.